A Randomized Trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer

Patients with advanced NSCLC (N=221) were randomized to Cisplatin-Paclitaxel or Cisplatin-Paclitaxel plus CADI-05, a TLR-2 agonist targeting desmocollin-3. Addition of CADI-05, improved median survival in Squamous cell subset (127 days, hazard ratio, 0.55; P=0.046) and in those receiving four cycles of chemotherapy (66 days, hazard ratio, 0.64; P=0.04) without adding systemic side effects.

from Cancer via ola Kala on Inoreader http://annonc.oxfordjournals.org/cgi/content/short/mdw608v1?rss=1
via IFTTT